Glioblastoma remains one of the most aggressive and devastating cancers, leaving patients and families with limited options and urgent need for progress. Yet, the treatment landscape is beginning to shift, projected to grow significantly by 2034 as science-driven approaches and novel therapies gain momentum. Merck’s landmark acquisition of Modifi Bio is more than a business milestone, it’s a signal of renewed hope in a field that has long faced barriers to investment and breakthroughs.

As we look toward 2026, sustaining this progress is not just important, it’s critical for the patients who cannot wait. The 7th Glioblastoma Drug Development Summit is your opportunity to accelerate innovation and bring life-changing therapies closer to those who need them most.

Over three transformative days, with six deep-dive workshops and 90+ leading experts from biotech, pharma, and investment, we will unite around one shared mission: to change the future for glioblastoma patients.

You’ll explore:

Innovating combination strategies to overcome resistance and improve outcomes for patients

Building robust preclinical and clinical frameworks that shorten the path from lab to bedside

Mobilizing investment and collaboration to deliver promising therapies faster

Harnessing AI’s power to unlock new insights and accelerate research

Join leading organizations, including Laminar Pharma, Medicenna, Merck, AstraZeneca, CNS Pharmaceuticals, Imvax, Tactical Therapeutics, and many more, as they turn scientific ambition into patient impact.

View the event here.